Pro: “The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.”

Hans-Christoph Diener

doi:10.1160/TH13-04-0277

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2013; 110(03): 493-495
DOI: 10.1160/TH13-04-0277

Pro/Contra Article

Schattauer GmbH

Pro: “The novel oral anticoagulants should be used as 1^st choice for secondary prevention in patients with atrial fibrillation.”

Hans-Christoph Diener

¹Department of Neurology and Stroke Center, University Hospital Essen, Essen, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
2 European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
3 Easton JD, Lopes RD, Bahit MC. et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511.
4 Diener HC, Eikelboom J, Connolly SJ. et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012; 11: 225-231.
5 Hart RG, Diener HC, Yang S. et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517.
6 Ntaios G, Papavasileiou V, Diener HC. et al. Nonvitamin-k-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 3298-3304.
7 Rasmussen LH, Larsen TB, Graungaard T. et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. Br Med J 2012; 345: e7097.